FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549	,

**OMB APPROVAL** 3235-0287 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Estimated average burden

hours per response:

0.5

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

			(	or Sec	ction 30(h) of the In	vestme	nt Cor	npany Act of	1940							
Name and Address of Reporting Person*     Goncalves Joana				2. Issuer Name and Ticker or Trading Symbol Cara Therapeutics, Inc. [ CARA ]							5. Relationship of Reporting Person(s) to Issue (Check all applicable)  Director 10% Owne  X Officer (give title Other (spec					
(Last) C/O CARA TH		,			e of Earliest Transa 7/2023	action (N	Month/	(Day/Year)			below) Chief Med	below]	)			
FL				4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Indiv	Individual or Joint/Group Filing (Check Applicable Line)					
(Street)										X	Form filed by On	e Reporting Per	son			
STAMFORD	CT	06902									Form filed by Mo Person	re than One Rep	porting			
(City)	(State)	(Zip)														
	1	Гable I - No	n-Derivati	ve S	ecurities Acq	uired,	Dis	posed of,	or Ber	neficially	Owned					
Date		2. Transactio Date (Month/Day/Y	Execution Date,		3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owner following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership				
						Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)			

Common	Stock		01/17/2023					<b>S</b> <sup>(1)</sup>		2,265	Г	\$10	.81 6	7,371	D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		nsaction of			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisa	ıble	Expiration Date	Title	Amount or Number of Shares				

## **Explanation of Responses:**

1. This sale was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person.

## Remarks:

/s/ Darren DeStefano, Attorney-in-Fact

01/19/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.